The phrase "active therapy for" is correct and usable in written English.
It can be used in contexts related to medical or psychological treatment where a specific therapy is being discussed.
Example: "The doctor recommended active therapy for the patient's rehabilitation process."
Alternatives: "therapeutic intervention for" or "treatment approach for".
Although aggressive pharmacological treatment of status epilepticus is well established in the emergency department and hospital settings, the relative risks and benefits of active therapy for status epilepticus in the prehospital setting are not known.
Patients with prior malignancies (except for non-melanoma skin cancers) were excluded unless any active therapy for such malignancy was >3 years from study entry.
To the best our knowledge, there are no systematic data available on patients with ACS who were not given active therapy for whatever reason.
The sample was stratified into three treatment categories: receiving an anti-angiogenesis agent, receiving other (non-anti-angiogenesis) therapy, and not currently receiving active therapy for their cancer.
The study suggests that oncologist trainees accept that nutritional status and nutritional intervention are important to outcome in patients receiving active therapy for malignancy.
With the present active therapy for malignancy and the management of thrombosis, the subsequent survival of cancer patients with and without thrombosis is expected to show further improvement.
More recently the introduction of very biologically active therapies for AD has led to increased use of MRI as a proactive safety assessment.
Limitation of active therapy was taken for 10 patients (45.5%), two of them were already considered in palliative care.
Metformin therapy will be titrated and proceed as outlined above, except that active therapy will continue for the full 24 months without a study-specified period of treatment withdrawal.
Secondary aims of the study are to determine the impact of the interventions on β-cell function while on active therapy and also for up to 9 months after withdrawal of medication.
Utility can be assessed by the occurrence of statistically or clinically significant differences between active therapy and placebo for a particular scale, especially if there appears to be a dose response.
